Researcher

Lili Zhang

Jiangsu Cancer Hospital

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

ERα36 is associated with SLC7A5/LAT1 expression, cervical cancer progression, and BNCT response: a translational study

Frontiers in Oncology

Translational study combining transcriptomic analysis, tissue immunofluorescence, and in vitro/in vivo cell models to characterize a signaling axis; lacks clinical trial evidence of BNCT response prediction or prognostic validation.

PreliminaryLu Zhang Wei Wang Lili Zhang

Reported

TCGA sample size296

GTEx control sample size10

Tissue microarray cervical cancer…99

AUG 11, 2026 · JOURNAL ARTICLE

Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study

Holistic Integrative Oncology

Real-world retrospective cohort with substantial sample size and mature follow-up reporting clinically relevant survival outcomes, but lacks randomized control and prospective design needed for practice-changing or strong evidence.

PromisingNanoparticle-based Drug Delivery Lili Zhang Jin Zhang

Reported

Sample size526

Median age53.0 years

Median follow-up856 days